Study participants
Cancer
BLOOD, CANCER
From 26 April 2017 to 30 September 2018, ten adults aged 52–62 years were recruited at the University of Michigan. This prospective feasibility single-center clinical study was done under FDA IND no. 132208. Participants were fully informed of the study and signed the consent form before any study procedures. The trial was reviewed by the University of Michigan Protocol Review Committee and was approved by the institutional review board. The Rogel Cancer Center’s and the University of Michigan Blood and Marrow Transplant Program’s DSMBs monitored the study quarterly. The study protocol specified comparing study patient samples to samples at identical time points of patients who were not on the study as external historical controls. Historical controls received allogeneic HCT at the University of Michigan from 6 July 2016 to 23 June 2017.